Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT03691714 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT03691714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03691714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
University of Cincinnati
Phase
Phase 2
Overall status
Completed
Start date
October 23, 2018
Completion date
December 1, 2024
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck neoplasms, metastatic cancer, recurrent head and neck cancer